Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

Onyx Pharmaceuticals, Inc. today announced updated safety data from the pivotal Phase 2b 003-A1 study, known as the 003 trial, demonstrating that carfilzomib is well-tolerated in heavily pre-treated relapsed and refractory multiple myeloma patients.

7 Dec 2009

ImmunoGen reports encouraging clinical data of IMGN901

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients whose disease had progressed on multiple prior treatment regimens.

6 Dec 2009

Bortezomib can improve control of GVHD and immune system recovery

A drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors, according to early clinical trial results to be presented by Dana-Farber Cancer Institute investigators at the American Society of Hematology's (ASH) annual meeting on Sunday, Dec. 6 (Abstract 48, Ernest N. Morial Convention Center, Room 243-245, 5:45 pm CT).

6 Dec 2009

Dana-Farber Cancer Institute receives 2009 MMRC Center of the Year Award

The Multiple Myeloma Research Consortium (MMRC) today announced that it has awarded the Dana-Farber Cancer Institute, and its clinical researchers, Kenneth Anderson, MD, and Paul Richardson, MD, with the 2009 MMRC Center of the Year Award.

5 Dec 2009

IMF to stage presentation on multiple myeloma at ASH annual meeting

The International Myeloma Foundation (IMF)—supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians—today said presentations at the annual meeting of the American Society of Hematology (ASH) will cover all stages of multiple myeloma, a major milestone in treating this and related cancers.

4 Dec 2009

Cancer patient “Statement of Principles” brought to the 2009 ASH meeting

A coalition of cancer patient advocacy organizations led by the International Myeloma Foundation (IMF) and the MDS Foundation (MDSF), will bring its cancer patient “Statement of Principles” to the 2009 Meeting of the American Society of Hematology (ASH) in New Orleans December 5th through 8th.

4 Dec 2009

Financial aspects of cancer treatment reduces compliance

New data being released today by the Association of Oncology Social Work (AOSW) demonstrate the extraordinary financial hardships that often complicate or compromise a patient’s battle against cancer. Sixty-three percent of oncology social workers surveyed said that financial issues reduce patients’ compliance with their cancer treatment – even though that treatment is key to their recovery. Forty percent of patients reported depleting their savings, while almost 30% reported dealing with bill collectors.

3 Dec 2009

Medical research experts explore new strategies to speed up treatments for medical disorders

Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugural Partnering for Cures meeting.

3 Dec 2009

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, announced today that it has entered into an option agreement with The University of Texas M. D. Anderson Cancer Center relating to an immunotherapy targeting cancer stem cells (CSCs) which has demonstrated in pre-clinical animal models significant abilities to target and destroy CSCs.

3 Dec 2009

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

Bristol-Myers Squibb Company today announced that more than 80 abstracts highlighting compounds from the company’s oncology portfolio will be presented at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held December 5-8 in New Orleans.

3 Dec 2009

FDA grants Fast Track designation for Keryx Biopharmaceuticals' KRX-0401

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of relapsed/refractory multiple myeloma.

3 Dec 2009

FDA grants Fast Track designation for AEterna Zentaris' perifosine

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company's PI3K/Akt pathway inhibitor compound, perifosine (KRX-0401), for the treatment of relapsed/refractory multiple myeloma.

2 Dec 2009

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.

2 Dec 2009

Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics

Seattle Genetics, Inc. today announced that data from its brentuximab vedotin (SGN-35) and dacetuzumab (SGN-40) programs will be reported at the upcoming 51st American Society of Hematology (ASH) 2009 Meeting and Exposition being held December 5-8, 2009 in New Orleans, Louisiana.

2 Dec 2009

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced that results from preclinical and clinical studies of two, novel blood forming agents, ACE-011 and ACE-536, will be presented at the 51st Annual Meeting of the American Society of Hematology at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

1 Dec 2009

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that clinical and preclinical data supporting the role of CAL-101, an oral, p110δ(delta) selective PI3K inhibitor in patients with hematologic malignancies, will be featured in two oral presentations at the upcoming 51st American Society of Hematology (ASH) Annual Meeting taking place in New Orleans, LA.

1 Dec 2009

Smoothie Factory supports Chronic Disease Fund’s mission with holiday fundraising program

More than 14-million Americans, with chronic or life altering diseases and cancer, can’t afford the medication they need because of the high out-of-pocket costs associated with their insurance coverage. That’s why the Chronic Disease Fund, a nonprofit organization, provides financial help to seriously ill Americans so they can get the medications they need to live without the fear of debt.

25 Nov 2009

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that presentations of clinical data for three product candidates employing its Targeted Antibody Payload (TAP) technology will be made at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition to be held in New Orleans, LA, on December 5-8, 2009.

25 Nov 2009

51st ASH meeting to feature 16 abstracts of MMRC

The Multiple Myeloma Research Consortium (MMRC) announced today that data from 13 of its clinical trials and three from the Multiple Myeloma Research Foundation (MMRF) Genomics Initiative, which analyzes tissue samples from the MMRC tissue bank, have been selected for oral or poster presentations at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH) to be held in New Orleans from December 5-8, 2009.

24 Nov 2009

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Nereus Pharmaceuticals, Inc., a pioneer in drug discovery from marine microbial sources, today announced positive interim results from a randomized Phase 2 clinical trial evaluating the vascular disrupting agent (VDA) plinabulin (NPI-2358) in combination with standard chemotherapy (docetaxel) in patients with advanced non-small cell lung cancer (NSCLC).

23 Nov 2009

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

ImmunoGen reports encouraging clinical data of IMGN901

Bortezomib can improve control of GVHD and immune system recovery

Dana-Farber Cancer Institute receives 2009 MMRC Center of the Year Award

IMF to stage presentation on multiple myeloma at ASH annual meeting

Cancer patient “Statement of Principles” brought to the 2009 ASH meeting

Financial aspects of cancer treatment reduces compliance

Medical research experts explore new strategies to speed up treatments for medical disorders

ImmunoCellular Therapeutics options immunotherapy targeting CSCs using abnormal Notch and Numb pathways

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

FDA grants Fast Track designation for Keryx Biopharmaceuticals' KRX-0401

FDA grants Fast Track designation for AEterna Zentaris' perifosine

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Data from brentuximab vedotin and dacetuzumab programs to be presented by Seattle Genetics

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Calistoga Pharmaceuticals to present data on its CAL-101 inhibitor at the 51st ASH meeting

Smoothie Factory supports Chronic Disease Fund’s mission with holiday fundraising program

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

51st ASH meeting to feature 16 abstracts of MMRC

Positive interim results from Nereus Pharmaceuticals' plinabulin VDA study for advanced NSCLC

Innovation in neuroscience drug discovery - eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Innovation in neuroscience drug discovery - eBook eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in